XX innovation is an independent, non-profit organisation redesigning the systems that shape women’s health outcomes.
We are science-led and solution-oriented, focused on delivering measurable impact across research, policy, funding and care.
Why “XX”?
“XX” is more than just a nod to biology. It stands for the spirit of exploration – embracing the unknown, daring to experiment, and welcoming bold collaboration at the intersections of science, society, and technology. Like the mathematical “X” for the unknown, we are here to uncover what’s hidden and spark meaningful disruption.
Our Vision
A world where women’s health is no longer side-lined, but centred in innovation, investment, and impact.
Meet Our Founder
Chrysi Sergaki, PhD
CEO and Founder of XX innovation
Chrysi founded XX innovation to turn evidence into outcomes for women’s health. She brings years of real‑world experience across policy, regulation, thought leadership, research, innovation and investment, applied to solving complex, systemic problems. Chrysi’s work has consistently focused on translation at scale: aligning incentives across diverse stakeholders, setting credible guardrails, and turning roadmaps into delivery. Prior to XX innovation, she led multi‑year, global initiatives that overcame translation barriers in challenging fields such as microbiome research, building partnerships across ecosystems to achieve measurable impact. With the United Kingdom as our hub, her goal is to bring that experience to Women’s Health through XX innovation, making it the go‑to organisation for catalysing action.
Behind this initiative stands a committed team who make the work possible.
Meet the Team
Manos Mastorakis, PhD
CFO
Manos co-founded XX innovation to advance women’s health by translating systemic challenges into investable, scalable solutions. He brings nearly a decade of experience across biotech investment research and strategic advisory, working at the intersection of life sciences, capital markets, and commercial strategy. His work focuses on identifying where innovation can deliver both meaningful impact and sustainable return, with a strong understanding of what makes solutions viable in real-world settings. Combining scientific insight with financial discipline, he brings a clear and structured approach to evaluating opportunities and turning them from concept to fundable, scalable ventures
At XX innovation, Manos leads the organisation’s financial and investment strategy, ensuring that solutions are not only impactful, but scalable and positioned to attract the capital needed to drive lasting change in women’s health.
Maria Katsarou
CSO
Maria joined XX innovation to drive systemic change in women’s health – repositioning women at the centre of healthcare innovation. She brings over six years of experience advising leading biotechnology and pharmaceutical organisations on translating scientific innovation into real-world impact. Her work spans the development and commercialisation of new medical technologies, shaping investment priorities, strategic direction, and pathways for adoption in healthcare systems. Combining scientific fluency with business acumen, she understands how complex systems shape success and can translate that complexity into clear decisions and tangible action.
At XX innovation, Maria leads the organisation’s strategic direction – identifying where the women’s health ecosystem can move forward, building the right partnerships, and driving the decisions that turn opportunity into lasting impact.
Anastasia Pakidi, PhD
Director of Programmes
Anastasia co-founded XX innovation to ensure scientific insight is translated into practical, real-world solutions in women’s health. She brings a background in immunology, combining analytical thinking with a hands-on approach to solving complex problems, alongside a strong understanding of the biological and clinical nuances within women’s health. Her work centres on bridging science and execution, shaping how ideas move from concept into structured, actionable programmes through close collaboration with scientific, clinical, and delivery partners. She brings structure and momentum to complex initiatives, ensuring scientific depth is matched with focused, effective execution.
At XX innovation, Anastasia leads programme development and scientific direction, ensuring initiatives are both grounded in evidence and delivered effectively in practice.
Merianne Mohamad, PhD
Director of Partnerships
Merianne co-founded XX innovation to advance women’s health by building the systems and partnerships needed to translate innovation into impact. She brings a background in molecular microbiology, with experience spanning research and translational science, including work in microbial genomics, diagnostics, and antimicrobial resistance at the intersection of healthcare and innovation. Her work focuses on connecting science, institutions, and stakeholders, ensuring that breakthroughs are supported by the structures needed for adoption in practice. She brings a strong understanding of how research, policy, funding, and delivery interact, enabling her to build collaborations that move ideas forward effectively.
At XX innovation, Merianne leads partnerships and ecosystem engagement, building the relationships and initiatives that enable innovation to reach the women who need it.
Our ethos
XX innovation was founded on the conviction that progress in women’s health requires more than good science. It demands systemic change.
Women’s health must be defined by data, not bias
Centring women’s biology and realities, not retrofitting
Sustainable progress requires coordination across sectors
Named owners, clear milestones, measurable outcomes